Multivariable analysis of VEGFC[/bi] as prognostic marker for overall and event-free survival
| Variable . | Overall survival . | Event-free survival . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| VEGFC* | 1.29 (1.02-1.63) | .038 | 1.37 (1.09-1.71) | .006 |
| Intermediate† | 2.14 (1.43-3.20) | < .001 | 1.69 (1.19-2.41) | .004 |
| Poor† | 3.79 (2.46-5.84) | < .001 | 3.01 (2.04-4.43) | < .001 |
| Age, decades | 1.12 (1.03-1.22) | .008 | 1.06 (.98-1.15) | .170 |
| WBC‡ | 1.35 (1.06-1.73) | .016 | 1.27 (1.01-1.60) | .038 |
| FLT3-ITD§ | 1.74 (1.32-2.28) | < .001 | 1.59 (1.23-2.06) | < .001 |
| NPM1 mutation‖ | .57 (.43-.77) | < .001 | .60 (.45-.79) | < .001 |
| CEBPA mutation¶ | .51 (.30-.84) | .008 | .58 (.36-.91) | .018 |
| Variable . | Overall survival . | Event-free survival . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| VEGFC* | 1.29 (1.02-1.63) | .038 | 1.37 (1.09-1.71) | .006 |
| Intermediate† | 2.14 (1.43-3.20) | < .001 | 1.69 (1.19-2.41) | .004 |
| Poor† | 3.79 (2.46-5.84) | < .001 | 3.01 (2.04-4.43) | < .001 |
| Age, decades | 1.12 (1.03-1.22) | .008 | 1.06 (.98-1.15) | .170 |
| WBC‡ | 1.35 (1.06-1.73) | .016 | 1.27 (1.01-1.60) | .038 |
| FLT3-ITD§ | 1.74 (1.32-2.28) | < .001 | 1.59 (1.23-2.06) | < .001 |
| NPM1 mutation‖ | .57 (.43-.77) | < .001 | .60 (.45-.79) | < .001 |
| CEBPA mutation¶ | .51 (.30-.84) | .008 | .58 (.36-.91) | .018 |
HR indicates hazard ratio; CI, confidence interval; intermediate, intermediate cytogenetic risk as defined in “Patients”; poor, poor cytogenetic risk as defined in “Methods”; WBC, white blood cell count; FLT3, fms-related tyrosine kinase 3; ITD, internal tandem duplication; NPM1, nucleophosmin 1; and CEBPA, CCAAT/enhancer binding protein α.
High VEGFC (ie, above the median VEGFC level) versus low VEGFC (ie, below the median VEGFC level).
Cytogenetic risk versus good cytogenetic risk.
WBC greater than 20 × 109/L.
FLT3-ITD versus no FLT3-ITD.
NPM1 mutation versus no NPM1 mutation.
CEBPA mutation versus no CEBPA mutation.